Low doses of ketamine seem able to dramatically improve obsessive-compulsive disorder, which has so far proved hard to treat. Carolyn Rodriguez’s lab at Stanford is seeking to understand how it works, with the hope of developing next-generation treatments that do not have ketamine’s side effects.